ACT
|
Australian Capital Territory
|
the Act
|
Gene Technology Act 2000
|
APVMA
|
Australian Pesticides and Veterinary Medicines Authority
|
BHK21
|
immortalised baby hamster kidney cell line number 21
|
CCI
|
Confidential Commercial Information as declared under section 185 of the Gene Technology Act 2000
|
CD
|
Cluster of Differentiation
|
CTLA-4
|
Cytotoxic T-Lymphocyte Antigen 4 (also known as CD152)
|
CTN
|
Clinical trial notification
|
CTX
|
Clinical trial exemption
|
DAFF
|
Department of Agriculture, Fisheries and Forestry
|
DIR
|
Dealings Involving intentional Release
|
DNIR
|
Dealings Not Involving intentional Release
|
DNA
|
Deoxyribonucleic Acid
|
EEV
|
external enveloped virus
|
fowlpox
|
Fowlpox virus
|
FSANZ
|
Food Standards Australia New Zealand
|
GM
|
Genetically Modified
|
GM-CSF
|
Granulocyte macrophage-colony stimulating factor
|
GMO
|
Genetically Modified Organism
|
GTTAC
|
Gene Technology Technical Advisory Committee
|
HREC
|
Human Research Ethics Committee
|
HIV
|
Human immunodeficiency virus
|
IATA
|
International Air Transport Authority
|
ICAM-1
|
Intercellular adhesion molecule-1 (also known as CD54)
|
ICH
|
International Conference on Harmonisation
|
ICH-GCP
|
International Conference on Harmonisation Good Clinical Practice standard
|
IL
|
interleukin
|
IMV
|
internal mature virus
|
ITR
|
inverted terminal repetitions
|
kb
|
kilobase(s)
|
LFA-1
|
Leukocyte function associated antigen-1 (also known as CD18)
|
LFA-3
|
Leukocyte function associated antigen-3 (also known as CD58)
|
LGA
|
Local government area
|
Mac-1
|
macrophage adhesion ligand-1 (also known as Integrin alpha M (ITGAM), complement receptor 3 (CR3) and CD11B)
|
ml
|
millilitre
|
mRNA
|
Messenger Ribonucleic Acid
|
NHMRC
|
National Health and Medical Research Council
|
NSW
|
New South Wales
|
NICNAS
|
National Industrial Chemicals Notification and Assessment Scheme
|
NYCBH
|
New York City Board of Health
|
OGTR
|
Office of the Gene Technology Regulator
|
PC2
|
Physical containment level 2
|
PCR
|
Polymerase Chain Reaction
|
PPD
|
Pharmaceutical Product Development Australia Pty Ltd
|
PROSTVAC-F
|
Recombinant fowlpox virus that expresses human genes encoding B7.1, LFA-3, ICAM-1 and modified PSA (also referred to in this document as GM fowlpox)
|
PROSTVAC-V
|
Recombinant vaccinia virus that expresses human genes encoding B7.1, LFA-3, ICAM-1 and modified PSA (also referred to in this document as GM vaccinia)
|
PSA
|
prostate-specific antigen
|
QLD
|
Queensland
|
Q-PCR
|
Quantitative Polymerase Chain Reaction
|
RARMP
|
Risk Assessment and Risk Management Plan
|
the Regulations
|
Gene Technology Regulations 2001
|
the Regulator
|
Gene Technology Regulator
|
REV
|
Reticuloendotheliosis virus
|
RNA
|
Ribonucleic acid
|
SA
|
South Australia
|
TGA
|
Therapeutic Goods Administration
|
TNFα
|
Tumor necrosis factor alpha
|
TRICOM
|
Triad of co-stimulatory molecules
|
USA
|
United States of America
|
UV
|
Ultra violet
|
VIC
|
Victoria
|
VIG
|
Vaccinia hyperimmune gamma-globulin
|
vaccinia
|
Vaccinia virus
|
WA
|
Western Australia
|
WHO
|
World Health Organisation
|
